Further analysis in ccRCC and pRCC indicated that the reduced BCL2L13 mRNA is independent of patients’ race, gender, age, lymph node metastasis status, clinical stages and tumor subtypes (Fig. 2, Additional file 1). Here, BCL2L13 is linked to nonpapillary renal cell carcinoma.